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RESUMO 
 
OBJETIVO: Estudar o impacto da hiperandrogenemia na fertilidade da mulher e os 
mecanismos específicos envolvidos, com especial ênfase no seu papel no ovário.  
 
DESENHO: Foi realizada uma extensa pesquisa na base de dados Pubmed online com 
os termos MeSh relacionados com o tema. A literatura referente ao impacto da 
hiperandrogenemia na fertilidade feminina foi revista. O nosso objetivo foi focado apenas 
em seres humanos, especificamente em mulheres, de forma que, estudos em animais 
e em homens foram excluídos, à exceção de transsexuais expostos a androgénios 
exógenos, pertencentes à nascença ao sexo feminino. Foram também excluídas 
mulheres com síndrome do ovário poliquístico, devido ao número de estudos já 
realizados em grande escala e para percecionar melhor o papel isolado da 
hiperandrogenemia. 
 
RESULTADOS: A hiperandrogenemia compromete o potencial reprodutivo das 
mulheres, apesar de haver disparidade entre estudos em células e tecido ovárico em 
seres humanos. Além disso, a hiperandrogenemia está associada a outros distúrbios 
metabólicos como a obesidade, a diabetes mellitus tipo 2 e dislipidemia. 
 
CONCLUSÃO: A hiperandrogenemia está intrínseca e claramente envolvida nos 
outcomes de (in)fertilidade. Contudo, trata-se de um tema pouco explorado e tivemos 
dificuldade em encontrar estudos prévios em mulheres que explorassem este tema. Os 
poucos estudos apresentados nesta revisão são limitados no alcance de mecanismos 
específicos que poderiam explicar o papel da hiperandrogenemia em mulheres inférteis 
ou subférteis. São necessários mais estudos em seres humanos sobre questões de 
fertilidade relacionada com a hiperandrogenemia. 
 
PALAVRAS-CHAVE: hiperandrogenemia; androgénio; ovário; folículos antrais; 
fertilidade; mulher 
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ABSTRACT 
 
AIM:  To study the impact of hyperandrogenaemia (HA) in women fertility and its specific 
mechanisms involved, with special emphasis to their role in the ovary.  
 
DESIGN: An extensive search was performed on the online database Pubmed with 
MeSh terms related to the theme. We reviewed literature regarding the impact of HA in 
female fertility. Our goal was focused only in humans, specifically women, so animal and 
men studies were excluded, in exception to female-to-male transsexuals (TSX). We also 
excluded women with polycystic ovary syndrome (PCOS) due to the large-scale number 
of studies already been made and to better perceive the HA role alone. 
 
RESULTS: HA impairs women reproductive potential, even though there are disparity 
between studies in human ovarian cells and tissue. Also, HA is associated with other 
metabolic diseases, such as obesity, type 2 diabetes mellitus and dyslipidaemia. 
 
CONCLUSION:  HA is clearly and intrinsically involved in (in)fertility outcomes. However, 
it is a very unexplored subject and we found it difficult to encounter previous studies in 
women exploring this theme. The few presented in this review are scarce in achieving 
the specific mechanisms that could explain HA role in infertile or subfertil women. More 
human studies are needed about fertility issues related to HA. 
 
KEYWORDS: hyperandrogenaemia; androgen; ovary; antral follicle count; female; 
fertility 
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DEDICATION 
 
 
 
 
 
Aos que, incondicionalmente, amo «por dois». 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pode ouvir-se ainda o seu 
bater contra o peito. 
Há tantos, tantos anos exposto 
à violência da luz do meio 
dia. Quase amargo, quase 
doce. Só a paixão o rouba 
à morte, o impede de ser 
panela esburacada 
onde o vento assobia. 
Ou pior: coisa viscosa, mole, 
inerme. Coração, 
matéria nobre. 
 
Matéria nobre | Eugénio de Andrade 
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ABBREVIATIONS 
ACTH – adrenocorticotropic hormone 
ADT – androstenedione 
AFC – antral follicle count  
AMH – anti-Müllerian hormone 
AR – androgen receptor 
ARs – androgen receptors 
ART – assisted reproductive technology 
BMI – body mass index 
CHO – total cholesterol  
DHEA – dehydroepiandrosterone 
DHEA-S – dehydroepiandrosterone sulfate 
DHT – dihydrotestosterone 
FAI – free androgen index 
FF – follicular fluid 
FPI – fasting plasma insulin 
FSH – follicle stimulating hormone  
FSH-R – follicle stimulating hormone receptor 
GCs – granulosa cells 
GDF-9 – growth differentiation factor 9 
HA – hyperandrogenaemia 
HDL – high-density lipoprotein 
ICSI – intracytoplasmic sperm injection 
IGF – insulin growth factor 
IGF-1 – insulin growth factor 1 
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LDL –  low-density lipoprotein 
LH – luteinizing hormone 
LH-R – luteinizing hormone receptor 
HDL – high-density lipoprotein 
HOMA-B – homeostatic model assessment of steady state beta cell function 
HOMA-S – homeostatic model assessment 
IR – insulin resistance 
IVF – in vitro fertilization 
MD – menstrual disorder 
MI – menstrual irregularity 
Ob – obese  
PCOS – polycystic ovarian syndrome 
PP – precocious pubarche 
PP14 – placental protein 14 
RM – recurrent miscarriages 
SHBG – sex-hormone binding globulin 
TG – triglycerides 
TGF-β – transforming growth factor beta 
TNF-α – tumor necrosis factor alfa 
TSX – female-to-male transsexuals 
TT – testosterone 
TFC – total follicle count 
T1DM – type 1 diabetes mellitus 
T2DM – type 2 diabetes mellitus 
WC – waist circumference 
WHR – waist-to-hip ratio 
       Vera Ângela Soares Ferreira                  Hyperandrogenaemia and Female Fertility 
 
viii 
 
 
INDEX 
 
RESUMO ........................................................................................................................................ ii 
ABSTRACT ..................................................................................................................................... iii 
DEDICATION ..................................................................................................................................iv 
ACKNOWLEDGEMENTS ................................................................................................................. v 
ABBREVIATIONS ............................................................................................................................vi 
INTRODUCTION ............................................................................................................................. 1 
HYPERANDROGENAEMIA .............................................................................................................. 2 
Hyperandrogenaemia: an overview .............................................................................................. 2 
Causes of hyperandrogenaemia.................................................................................................... 3 
The implication of this metabolic disturbance in the feminine reproductive system .................. 4 
HYPERANDROGENAEMIA AND FEMALE REPRODUCTIVE POTENTIAL........................................... 8 
IMPACT OF HYPERANDROGENAEMIA ON WOMEN MORBIDITY, QUALITY OF LIFE AND 
ECONOMICS ................................................................................................................................ 15 
CONCLUSIONS ............................................................................................................................. 16 
REFERENCES ................................................................................................................................ 17 
 
 
1 
 
INTRODUCTION 
Androgens have always been associated to a key functional role in the maintenance of 
sexual behaviour and male reproduction (Walker, 2009). Nonetheless, online Mendelian 
Inheritance in Man lists the expression of these steroid hormones in 27 different tissues, 
including the ovary. 
Androgens exert their physiological actions by interaction with their cognate 
intracellular receptor. The human androgen receptor (AR) gene is located on 
chromosome Xq11-12 and spans a ~180Kb DNA, which encodes a 110 kDa protein 
(Lamont and Tindall, 2010) AR functional axis is involved in many human metabolic 
processes and therefore it is not surprising that AR malfunction plays a central role in 
the pathogenesis of many diseases including neurodegenerative diseases (Borgia et al., 
2017), cancer (Shi et al., 2017) and developmental disorders (Greeley et al., 2017; Ittiwut 
et al., 2017). 
AR deregulation and association to pathogenesis define AR as a major target in 
hormonally responsive diseases, such as female hyperandrogenaemia.  
The present review will present the influence of androgens with focus on its 
excess in female reproductive physiological processes and fertility potential. Therefore, 
in order to carry out this task we selected experimental studies from Pubmed database, 
searching for MeSh (Medicals Subjects Headings) terms related with androgen and 
ovary. Contributions to sexual health and psychosocial well-being will also be focused. 
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HYPERANDROGENAEMIA 
 
Hyperandrogenaemia: an overview 
Hyperandrogenaemia (HA), or androgen excess, is one of the most common endocrine 
disturbances in women. HA functional disorders include polycystic ovary syndrome 
(PCOS), idiopathic hyperandrogenism, idiopathic hirsutism, non-classic congenital 
adrenal hyperplasia, androgen secreting tumours and other rare disorders (Ehrmann, 
2005), whereas HA clinical features consist in male distribution patterns, such as 
hirsutism and voice changes, acne, and androgenic alopecia (Cousen and Messenger, 
2010).  The majority of the patients with HA will develop PCOS. Nonetheless, due to the 
large amount of scientific information devoted to this condition, we will not pursue this 
subject further. This endocrinopathy affects particularly women of reproductive age. 
Regarding clinical signs of hyperandrogenism, hirsutism and acne seem to be equally 
frequent (12.2% prevalence), whereas alopecia is less common (1.7% prevalence). 
Concerning functional disorders of androgen excess, PCOS and idiopathic hirsutism are 
equally frequent (5.4% prevalence) followed by idiopathic HA (3.9% prevalence) 
(Sanchon et al., 2012). Already with regard in non-classic congenital hyperplasia or 
androgen secreting tumours and other rare disorders these conditions account for 3% 
and less than 1% of HA cases (Carmina et al., 2006). 
Among the clinical manifestations of HA, hirsutism is the one that has the 
strongest value in the disease diagnostic of women with androgen excess. Hirsutism is 
defined as excessive growth of terminal hair in women in a male-like pattern (Kuhn, 
1972). Its presence is determined through the modified Ferriman-Gallwey score 
(Ferriman and Gallwey, 1961; Hatch et al., 1981). Hirsutism results from increased 
androgen production and/or increased sensitivity of the pilosebaceous unit to androgens 
(Randall, 1994). Reproductive-aged women have tendency to develop more body hair 
until menopause, while in postmenopausal women this tendency is observed in facial 
hair. The other manifestations of HA common in women are acne and androgenic 
alopecia. These androgenic skin changes may be observed independently of hirsutism 
though these isolated symptoms are not used as a diagnostic criterion for HA. In these 
cases, an association with hirsutism or menstrual dysfunction should be considered for 
HA diagnose. Acne is a chronic inflammatory disease of the pilosebaceous unit in which 
the androgen-induced increased sebum production plays a crucial role (Khondker and 
Khan, 2014). The cellular and molecular mechanisms by which these hormones exert 
their influence on the sebaceous gland are hitherto unknown (Shaw, 2002). The severity 
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of acne is classified accordingly the American Academy of Dermatology guidelines 
(Pochi et al., 1991). Androgenic alopecia is an androgen-dependent pattern of hair loss, 
scored through the Ludwig scale (Paik et al., 2001). While in adult women, acne severity 
is correlated with increased serum androgen levels (Borgia et al., 2004) and acne’s 
absence is observed in women who lack functional ARs (Imperato-McGinley et al., 
1993), women with androgenic alopecia have slightly increased serum androgen levels 
of but increased levels 5α-reductase and ARs, and decreased levels of cytochrome P450 
(Drake et al., 1996; Orme et al., 1999; Rebora, 2004; Cousen and Messenger, 2010). 
 
Causes of hyperandrogenaemia 
HA can be caused by genetic defects in steroid hormone expression (Mason and Franks, 
1997) and primary abnormalities of the hypothalamic-pituitary unit, the ovary and the 
adrenal gland (Yen, 1980 and Barbieri et al., 1986). Furthermore, although the specific 
mechanisms remain controversial, obesity has been also linked to HA (Diamanti-
Kandarakis and Bergiele, 2001). The proposed underlying mechanisms point out that 
hyperinsulinemia and insulin resistance (IR) might be involved (Kissebah et al., 1982), 
having into account the common features between obesity and IR, that is obesity leads 
to IR and, in turn, IR leads to obesity, both displaying increased hepatic fat deposition 
(Nicholas et al., 2016). 
Not in an independent manner, once connected with obesity as well, 
hyperinsulinaemia has been also related with HA in reproductive aged women (Burghen 
et al., 1980; Kissebah et al., 1982; Taylor et al., 1982; Chang et al., 1983). To explain 
this phenomenon, it is hypothesized that it is hyperinsulinemia the cause of ovarian 
hyperandrogenism or that hyperandrogenism causes IR and compensatory 
hyperinsulinemia, or even an unknown factor causes both hyperinsulinemia and 
hyperandrogenism (Barbieri et al., 1986). Several studies and clinical reports have 
clearly shown that link but the exact underlying mechanisms are poorly understood 
(Barbieri and Ryan, 1983; Poretsky, 1991). There is according data mentioning the point 
of androgen excess production, mainly by the ovaries, as result of hyperinsulinaemia 
associated with IR. In fact, as described above, insulin is one of the factors involved 
(Poretsky and Kalin, 1987). In addition, reciprocal potentiation between hyperinsulinemia 
and HA is postulated (Moghetti et al., 1996). Indeed, insulin and androgen levels act in 
the ovary in a synergic way, that is, insulin acts to enhance luteinizing hormone (LH) 
responsiveness leading to greater steroidogenesis (Arthur et al., 1994) and therefore 
androgen production (Dickerson et al., 2010). Many women with functional ovarian 
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hyperandrogenism have hyperinsulinemia (Burghen et al., 1980; Taylor et al., 1982; 
Chang et al., 1983). In these women, insulin may act alone or synergistically with LH to 
increase ovarian androgen production (Barbieri et al., 1986).  
 
The implication of this metabolic disturbance in the feminine 
reproductive system  
Androgens are produced in different organs but most of their production takes place in 
the adrenal glands and in the ovary (Lebbe & Woodruff, 2013). The concentration ranges 
for testosterone (TT) is 0.5-2.0 nmol/l and its precursor, androstenedione (ADT) is 3.0-
7.0 nmol/l. Pathways of androgen production in thecal and granulosa cells are reviewed 
by Norman (Norman, 2002). Though the exact role of androgens in the female 
reproductive system remains unclear, it is of knowledge that HA exerts a negative impact 
(Arlt, 2006).  
The zona reticularis of the adrenal gland cortex produces the androgens 
dehydroepiandrosterone (DHEA), an important precursor of sex steroids and ADT, 
activated by the pituitary cortical androgen-stimulating hormone and insulin growth factor 
1 (IGF-1) (Gurnell et al., 2008; Sá and Sousa, 2014). The DHEA is the unic source of 
sex steroids for all tissues, except the utherus, in postmenopausal women. For this 
reason, it seems that DHEA might be involved in mechanisms related with the symptoms 
found after menopause, such as vaginal atrophy, bone loss, fat accumulation, type 2 
diabetes mellitus (T2DM), skin atrophy, cognition problems and memory loss (Labrie, 
2010). The adrenal gland responds to adrenocorticotropic hormone (ACTH) (Gebre-
Medhin et al., 2000). 
In the ovary, androgen production occurs in theca cells and in the ovarian stroma. 
Several substances are thought to participate in the increase of androgen levels, 
including LH, activin, tumour necrosis factor alpha (TNF-α), Insulin growth factors (IGFs) 
and interleukins (Norman, 2002). LH release stimulates the ovary to raise the production 
of 17-α-hydroxyprogesterone, which is overproduced in case of HA. Activin, a dimeric 
protein of β-subunits that belongs to the transforming growth factor β (TGF-β) family, 
plays a role in the development and continued existence of healthy oestrogenic follicles, 
preventing premature luteinisation. In fact, activin allows that the follicle stimulating 
hormone receptor (FSH-R) starts to be expressed in the granulosa cells (GCs) in the 
primary follicle. FSH-R are present in all GCs since the secondary follicle stage, where 
the growth differentiation factor 9 (GDF-9), also a TGF-β secreted by the oocyte, acts 
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through mitogenic effect, allowing GCs growing. GCs are the only cells to express FSH-
R. Another molecule secreted by GCs is KIT-L, involved in the formation of the theca 
interna (Sá and Sousa, 2014). Inversingly, follistatin leads to the luteinisation process 
(Findlay, 1994). TNF-α is one of the follicular fluid components, but it remains unclear if 
alteration of TNF-α levels interfere with oocyte developmental competence. Also, TNF-α 
functions consist in apoptosis regulation, which leads to follicular atresia (Roby and 
Terranova, 1988; Adashi et al., 1990; Wang et al., 1992; Van Voorhis et al., 1994; Lee 
et al., 2000).  IGFs play an important role on granulosa cell cytodifferentiation (Garzo 
and Dorrington, 1984). Glister et al. reported the importance of IGF peptide 3 in keeping 
androgen production by theca cells and that the inhibitory action of bone morphogenic 
proteins on androgen production is related to their inhibition role on ILP-3 signalling, 
which seems to be mediated via down-regulation of the nuclear transcription factor 
steroidogenic factor-1 (Glister et al., 2013). Also, it has been reported that androgen 
production is also achieved by hormone stimulation; insulin and IGF-1 are able to 
stimulation of androgen production (Barbieri et al., 1986). Angiogenesis is very important 
and depends on the vascular endothelial growth factor, with the urge of blood vessels in 
preantral theca interna GCs.  
Regarding female fertility, the ovary production of androgens plays a central role 
(Glister et al., 2013). Thus, it is important to be aware of its known physiology and 
biochemical paths. Folliculogenesis and steroidogenesis is schematically represented in 
Figure 1. Each pathway potentially could be the causal HA, when disturbed. 
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Figure 1. (a) Menstrual cycle and Folliculogenesis. (b) Steroidogenesis. LH, luteinizing hormone; LH-R, LH receptor; FF, 
follicular fluid; FSH, follicle stimulating hormone; FSH-R, FSH receptor; GCs, granulosa cells; P450c17, cytochrome 
P450c17; ZP, zona pellucida; 3β-HSD, 3β-hydroxysteroid dehydrogenase; 17β-HSD, 17β-hydroxysteroid 
dehydrogenase. Adapted from Leão et al., 2014; Li et al., 2014; Sá and Sousa, 2014 and Kierszenbaum et al., 2016. 
 
Androgen levels are higher in the mid cycle phase of the menstrual cycle: also, 
they decrease with age or ovary removal (Norman, 2002). Androgen receptors (ARs) are 
expressed in all types of cells present in the ovarian follicle, including the oocyte, 
granulosa and theca cells and the cortical stroma (Sen and Hammes, 2010). Increasing 
AR concentrations are detected in granulosa cells (GCs) from the primary stage onward, 
peaking in the antral stage (Sen and Hammes, 2010). Several growth factors and 
(a) 
(b) 
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cytokines act in the ovary in autocrine or paracrine manner (Rice et al., 2007). TT and 5-
dyhidrotestosterone (5-DHT) are the only hormones capable to bound to AR. Thus, 
androgens have an important role in folliculogenesis and its excess might infere with 
folliculogenesis normal course. LH and FSH pulses, through hypothalamus hypophyses 
axis, were already been well documented by Rojas et al. (Rojas et al., 2015).  
Noteworthy, the exact role of androgens in women remains controversial 
(Norman, 2002). Contributions to sexual health and well-being have been mentioned 
(Arlt et al., 1999; Gebre-Medhin et al., 2000; Norman, 2002) and will be discussed below, 
despite no further clarification of the underlying mechanisms involved was added. 
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HYPERANDROGENAEMIA AND FEMALE REPRODUCTIVE 
POTENTIAL 
Female HA is well recognized to play detrimental impact on fertility (Lebbe and Woodruff, 
2013). However, its underlying mechanisms are poorly understood. Our aim was to 
understand more clearly the impact of HA in fertility, with emphasis to the specific 
mechanisms that might be involved. Studying the human ovary and its constituents is 
truly challenging. Indeed, on one hand, besides ethical issues in human ovarian tissue 
management, the HA focus has been in large scale applied to PCOS. As mentioned 
before, this consequence of HA was excluded of our scope of work. On the other hand, 
to assemble human oocytes studies concerned about the particular mechanisms 
involved is like to find «a needle in a haystack». The articles selected having this matter 
into account were very low, in the view of the extensive search, and are listed in Table 
1. Already in 1990, Apter and Vihko mentioned the necessity of more studies, reporting 
the association between HA and poorer fertility outcomes: women with HA had lower 
pregnancy rates and it seemed that HA was connected to previous HA in puberty (Apter 
and Vihko, 1990). 
9 
 
Table 1: Hyperandrogenaemia consequences on female fertility potential. 
Reference Type of work Country  Aim Study group Relations 
Cui et al., 2016_RE Cross-sectional study 
 
China Age-specific AMH distribution 
Association of AMH with androgenic and 
metabolic profiles at different ages 
6763 women, 0-64y, divided in 4 phases: 
   Childhood (0-10y, n=739) 
   Adolescence (11-18y, n=471) 
   Reproductive age (19-50y, n=5500) 
   Advanced age (>51y, n=53) 
AMH: 
   ↑ until peak at 18y, ↓ during the reproductive age period; low level above 0 
onward;  
   Negatively correlated with TT in childhood; 
   Positively correlated with TT and FAI (adolescence and reproductive phases); 
   Not correlated to BMI, IR or dyslipidaemia. 
Hvidman et al., 
2016_HR 
Prospective cohort 
study 
Denmark Do infertile patients <40y have a lower 
ovarian reserve, estimated by AMH and 
AFC? 
382 infertile women 
350 without history of infertility, control group 
Infertile patients had similar AMH levels and AFC  
West et al., 2014_HR Prospective cohort 
Finland 
 
 Do teen girls with MI have ↑androgen 
levels and ↑risk of infertility? 
 
16y girls and later 26y, n=2033 (questionnaire) 
     at 16y with MI (n=482) 
     at 16y without MI (n=1252)   
At the age of 26y, MI and androgenism signs when 16y have: 
     Hirsutism:     ↓ [SHBG] ↑ FAI 
     Acne: ↑[TT] ↓ [SHBG] ↑ FAI 
No link to ↑ risk of childlessness 
Irez et al., 2011_AGO Clinical trial Turkey Association between different of AMH 
basal levels 
Oocyte-embryo quality and IVF 
outcomes 
209 infertile women undergoing IVF with ICSI AMH: 
   Negative correlation with age; 
   Positive correlation with gonadotropin, AFC and the number of oocytes; 
   Ongoing pregnancy rate > in percentiles 25-90%. 
Dickerson et al., 
2010_HR 
Prospective study UK
  
 
Influence of IR and androgen status in 
non-PCOS women 
Infertile women without PCOS, with regular menstrual cycle, undergoing 
an ART cycle, n=49 
Positive correlation with FAI, TT and BMI.  
Positive correlation of TFC and FAI.  
Negative correlation of HOMA with SHBG.  
No correlation between HOMA or FPI and TFC. 
No correlations between number of oocytes retrieved, fertilization or cleavage rates 
and FPI, HOMA and androgen levels. 
Eilso Nielsen et al., 
2010_MHR 
Cohort study Denmark 
Japan  
Determine expression of AMH-r2 and 
correlate to expression of CYP19, FSH-R 
and LH-R and to the normal profile 
24 women, 64 follicles, 15-37y  In FF, AMH levels (ligand) had a negative correlation with mRNA expression of the 
aromatase (CYP 19); [AMH] had no correlation with androgens. 
In GC, AMH-r2 has a positive correlation with FSH-R expression and no correlation with 
androgens. Negative correlation with progesterone. 
Nardo et al., 2009_HR Cohort study 
 
UK Relationship between IR, androgens and 
AMH 
AMH contributes to altered 
folliculogenesis? 
232 women, 22-41y, IVF work-up prior to 1rst IVF treatment, n=232  
   non-PCOS women, n=183 
AMH levels: 
 ↑ with AFC, LH, insulin and TT levels, FAI and HOMA-IR; AMH levels  
↓ with HOMA-B and SHBG levels 
Ibáñez et al., 
2002_TJCEM 
Prospective Cohort 
study 
 
Spain  
UK  
Belgium 
Novel therapeutic avenues of 
mechanisms link hyperinsulinemic 
hyperandrogenism 
31 HA and hyperinsulinemic women, 18-22y, 9 months: 
     10 FT, flutamide monotherapy         
       8 MT, metformin monotherapy     
     13 CT, flutamide-metformin combined therapy 
CT women: 
<hirsutism, androgen levels and dyslipidemia than women who received FT 
<anovulatory cycles 
Okon et al., 1998_FS Retrospective study 
 
USA [Androgen]plasma levels in RM   
Correlate to [PP14] uterine and [PP14]plasma 
43 non-PCOS women with RM, 20-40y 
18 women without RM, control group 
 
>[TT] on days LH-7 and LH-4; >[ADT] on day LH-7; >TT SHBG ratios in women with RM 
on days LH-7, LH+0 and LH+7. 
Negative correlation between [TT]follicular and [androgen]plasma and PP14uterine 
Pache et al., 
1991_RH 
Case control Netherlands Androgens action in the ovary 17 women TSX (29 ovaries) 
13 regularly cycle women (14 ovaries)  
-  ovaries enlarged 
- ↑cystic follicle (2x) 
- ↑atretic follicle (3.5x) 
- ↑collagenized and thicker (3x) cortex 
Apter and Vihko, 
1990_JCES 
Longitudinal cohort 
study (1975→1987) 
Finland Endocrine features and factors related 
to fertility 
200 girls, 7-17y→not accomplished pregnancy women, n=26 vs. women 
who became pregnant, n=18, 20-30y 
↓pregnancy rate 
HA correlated with previous HA in puberty 
AFC, antral follicle count; AMH, anti-Müllerian hormone; AMH-r2, anti-Müllerian hormone receptor 2; BMI, body mass index; CYP19, cytochrome-P-19; FAI, free androgen index; FF, follicular fluid; FPI, fasting plasma insulin; FSH-r, follicle stimulating receptor; 
HDL, high-density lipoprotein;  HA, hyperandrogenaemia; HOMA, homeostatic model assessment; ICSI, intracytoplasmic sperm injection; IR, insulin resistance; IVF, in vitro fertilization; LDL, low-density lipoprotein; LH-r, luteinizing hormone receptor; MD, menstrual 
disorder; MI, menstrual irregularity; Ob, obese; PP14, placental protein 14; RM, recurrent miscarriage; SHBG, sex-hormone bind globulin; TFC, total follicle count; TSX, female-to-male transsexuals; TT, testosterone; WC, waist circumference; WHR, waist-hip 
ratio. 
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HA link to recurrent miscarriages (RM) was pointed out (Okon et al., 1998; 
Cocksedge et al., 2008). Okon et al., 1998 went further and hypothesized a mechanism 
that could explain this association: HA might result in an abnormal secretory 
endometrium through high androgens concentration with impact on placental protein 14 
(PP14) production, a protein involved in embryo implantation, lowering its uterine levels. 
Also, they obtained higher concentrations of ADT in the follicular phase in women with 
RM (Okon et al., 1998). Pache et al. had the opportunity to study ovaries from female-
to-male transsexuals (TSX), that is, exposed to higher exogenous androgen levels for 
some period. The result in ovarian TSX tissue was an alteration in follicle development 
(follicle growth and follicle arrest induction, thicker theca interna), collagenization and 
thickening of the ovarian cortex and the well-recognized cystic alterations (stromal and 
theca interna hyperplasia) (Pache et al., 1991). Thus, both exogenous and endogenous 
androgen excess exposure decreases reproductive outcomes. Recently, Panidis et al. 
reviewed this theme as a two-sided capacity of androgens dependency on its levels. In 
normal levels, androgens are essential for follicle development but in hyperandrogenism, 
it can be compromised (Panidis et al., 2015). In agreement, Prizant et al., also mentioned 
the importance of a balance in androgen levels to normal reproductive function (Prizant 
et al., 2014). The negative effects of androgens on follicle development have been 
reviewed by Gleicher et al., 2011. It seems that androgens negative impact is more 
pronounced in the earliest stages and two ways to explain it are presented: the genomic, 
through ARs, and the non-genomic, for example diffusion (Gleicher et al., 2011).  
Efforts have exhaustively been made to understand if anti-Müllerian hormone 
(AMH) can be a fiable marker of the human ovarian reserve, which has a tremendous 
prognostic value in women who seek to conceive. Decreased ovarian reserve 
compromises in vitro fertilization (IVF) success once it is associated to aneuploidy, 
embryo defective development, lower implantation success and higher spontaneous 
miscarriages (Irez et al., 2011; Lebbe and Woodruff, 2013). This can be explained by the 
correlations between AMH concentrations and the human ovarian reserve. Also, age is 
related to ovarian reserve. Indeed, the human ovarian reserve decreases along the years 
until menopause. With the decrease of the ovarian reserve, the oocyte quality also 
decreases because of women aging. Thus, oocyte morphology and chromosome 
anomalies such as aneuploidy occur, which leads to higher number of spontaneous 
abortion, to embryo and fetal compromised development and to decrease in the number 
of oocyte achieving metaphase II stage. Androgens are also regarded as one of the 
factors that might affect the ovarian reserve and recently, it has been postulated that 
androgens exert effect in the regulation of AMH expression and/or levels (Lebbe and 
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Woodruff, 2013). Thus, its correlation to AMH from adolescent to reproductive stages 
leads researchers to believe that there is a link between AMH and androgens (Cui et al., 
2016). Nardo et al. demonstrated this association in infertile women (Nardo et al., 2009). 
Eilso Nielson obtained no correlations between AMH and androgens, but probably this 
can be explained by the fact that the FF was extracted from small antral follicles from 
ovaries removed surgically (Eilso Nielsen et al., 2010).  Irez et al. studied different AMH 
concentrations in women under IVF and concluded that AMH in extreme concentrations, 
that is, under 1.4 ng/mL and above 8.06mg/mL were associated to poorer ongoing 
pregnancies (Irez et al., 2011). It is of importance that AMH concentrations are studied 
once its helps to predict the oocyte quality and assisted reproductive technology 
outcomes. For instance, it is known that higher concentrations of AMH mean that more 
follicles are available to be stimulated to mature, that is, the ovarian reserve is higher. 
Recently, Hvidman et al. studied women under forty years-old to an attempt to establish 
a possible association between AMH levels and AFC. AMH levels were not correlated to 
AFC, despite previously positive correlations between AMH levels and AFC found by 
Irez et al. and Nardo et al. (Nardo et al., 2009; Irez et al., 2011; Hvidman et al., 2016). 
Once again, a struggle is patent in finding the pathways implied.  
HA might be the responsible or even the consequence of other metabolic 
disorders. Ibánez et al. studied hyperinsulinaemic and hyperandrogenaemic women 
receiving combined therapy flutamide-metformin, anti-androgen and insulin sensitizing 
drugs, respectively. The authors concluded that women who received combined therapy 
had higher ovulatory cycles than women who received monotherapy. This phenomenon 
leads to think that HA is related to hyperinsulinaemia, and thus to IR, and that both alter 
female fertility. The concomitant dyslipidemia seemed to be a consequence of HA in the 
presence of hyperinsulinaemia (Ibanez et al., 2002). As we noticed, the intricate relations 
to other metabolic disorders, and its relations are listed in Table 2.  
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Table 2: Hyperandrogenaemia and its relations to other metabolic disturbances. 
Reference Type of work Country  Aim Study group Results  
Pinola et al., 
2012_HR 
Cohort study 
Questionnaire 
Finland  
 
Are self-reported menstrual 
disorders associated with HA 
and metabolic disturbances as 
early as in adolescence? 
Teen girls, 15-16 y, n=2448 
      MD group, with menstrual disorder, n=709 
      Without MD, n=1739 
 
 > androgen levels in MD women 
Whole population study: 
   Positive correlation between BMI and WHR, FAI, FPI, TG and LDL 
   Negative correlation between BMI and HDL, SHBG and  
   Negative correlation between HOMA-S and age at menarche 
 
Samara-
Boustani et al., 
2012_EJE 
Cross-sectional study 
 
France  The pubertal development, 
hormonal profiles and 
prevalence of hirsutism and 
MD between Ob and T1DM 
Ob adolescent girls, n=96 
Adolescent girls with T1DM, n=78 
Ob girls: 
   < age at pubarche, thelarche and menarche             
    >hirsutism 
   No difference in androgen levels between hirsutism and MD groups 
   > androgen levels in hirsute obese women 
 
Yasmin et al., 
2012_EJOGRB 
Cross-sectional, 
observational study 
 
UK  Association between BMI and 
different androgen 
parameters  
121 Ovulatory women  
     BMI≤30 Kg/m2, n=95 
     BMI>30 Kg/m2, n=37 
 
Positive correlations between BMI and FAI 
Negative correlations between BMI and SHBG 
No correlations between BMI and TT 
↓↓insulin sensitivity with ↑ BMI 
 
Zhou et al., 
2012_CE 
Cross-sectional study 
 
China  
 
Normal cut-off value for the 
FAI in reproductive-age 
Chinese women  
1526 women ,20-45y 
     Control group, n=444, non-HA  
 
HA women: 
   > BMI, acne score, androgen levels, CHOL and TG; 
   > MI, hirsutism, acne, IR or DM, Ob and fatty liver  
 
Wei et al., 
2010_BMCMD 
Cross-sectional study Australia Associations between 
menstrual pattern, TT, SHBG, 
FAI and bone mass 
Women, n=382 (11%), 26-36y, menstrual pattern (questionnaire) 
     with irregular cycles, n=41 
     with regular cycle n=341 
>FAI and <SHBG in MI women  
 
 
Wei et al., 
2009_O 
Cross-sectional study Australia Association between BMI, 
WC, WHR and menstrual cycle 
pattern with hormonal factors  
726 women,26-36y with different body composition measures and menstrual cycle 
pattern (questionnaire)  
BMI, WC and WHR were positively correlated with androgen and insulin levels.  
McCartner et 
al., 2006_JCEM 
Cross-sectional study USA Is pubertal obesity associated 
with HA? 
Peripubertal girls, n=76, 7-17y 
     Ob group, n=41                        
     Non-obese group, n=35 
>androgen levels in obese women 
Early pubertal girls: BMI correlated positively with androgen and insulin levels 
 
Ibáñez et al., 
1999_CE 
Cohort study Spain Can abnormal IR, Dyslipidemia 
and HA also be detected in 1rst 
degree relatives of PP girls? 
1rst degree relatives of PP girls, n=60  
     Women, n=30                                                  
          Hirsutism, n=10 , 5  with MI 
          Non-hirsutism, n=20, 2 with MI  
     Control group      
     Men, n=30 
Hirsute woman with MI relatives  
     >androgen levels  in  
     >abnormal glucose tolerance 
     poor lipid profile 
 
ADT, androstenedione; AFC, antral follicle count; AFM, abdominal fat mass; AMH, anti-Müllerian hormone; BMI, body mass index; CHOL, cholesterol; DHEA-S, dehydroepiandosterone sulphate; FAI, free androgen index; FF, follicular fluid; HA, hyperandrogenaemia; HDL, high-density 
lipoprotein; LDL, low density lipoprotein; HOMA-S, homeostasis model assessment; IR, insulin resistance; LDL, low-density lipoprotein; MD, menstrual disorder; MI, menstrual irregularity; Ob, obese; PP, precocious pubarche; SHBG, sex-hormone bind globulin;  TG, triglycerides; TT, 
testosterone; T1DM, Type 1 diabetes mellitus; WC, waist circumference; WHR, waist-hip ratio. 
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HA is reported to be related to menstrual irregularity (MI) in several studies (Wei 
et al., 2009; Wei et al., 2010; Pinola et al., 2012) which is associated to anovulation. 
However, we need to bear in mind that menses regularity was in some studies achieved 
by questionnaire, which is a limitative aspect. Recently, West et al. performed a 2033 
women prospective cohort to verify if teenage girls with MI at the age of 16 years-old 
would have HA and impaired reproductive outcomes at the age of 26 years-old. Teen 
girls with hirsutism and acne at 16 years-old displayed elevated androgen levels later, 
which suggests the early onset of HA (West et al., 2014). 
Of interest, considering the obesity pandemics worldwide and the remarkable 
increase in T2DM as well, it is alarming to realize that hyperinsulinemia related to obesity 
might contribute to HA (Anderson et al., 2014). Ibáñez et al. suggested that there might 
be a genetic basis for this association, based in the higher prevalence of dyslipidemia, 
IR, and HA in first degree relatives of girls with a history of precocious pubarche (PP) 
(Ibanez et al., 1999). Furthermore, in a posterior study, Ibáñez and colleagues also 
studying girls with PP mentioned that abdominal fat mass and truncal fat mass were 
positive related to fast plasma insulin, androgen and lipid levels (Ibanez et al., 2003). 
Panidis et al. also had results consistent with these correlations between IR, obesity and 
HA, although in a small sample of women (Panidis et al., 2015). The influence of IR and 
in androgen excess was studied by Dickerson et al. They showed that in women without 
PCOS, IR and HA can have impact in ovary function. Specifically, it is proposed that 
relatively higher level of insulin stimulates follicle recruitment or development (Dickerson 
et al., 2010). Noteworthily, Zhou et al. found higher prevalence of IR or T2DM, obesity 
and fatty liver in a large sample of HA women in the reproductive age, which gives further 
information pointing to a correlation between HA and metabolic disorders (Zhou et al., 
2012). 
MacCartner et al. studied obesity in peripubertal girls and its influence in 
androgen levels. They had even higher androgen levels in early puberty (McCartney et 
al., 2006). Also, as mentioned by Cockesedge et al., women with higher free androgen 
index (FAI) have higher body mass index (BMI), which supports the correlation between 
HA and obesity (Cocksedge et al., 2008). Furthermore, BMI, waist circumference (WC) 
and waist-to-hip (WHR) ratio were positively correlated with FAI and insulin levels. 
Fasting plasma glucose association with androgens is consistent with the literature (Wei 
et al., 2009). This phenomenon was also observed by Samara-Boustani et al., studying 
an obese group of adolescent girls which showed earlier age of pubarche, thelarche and 
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menarche and higher prevalence of MI and hirsutism and androgen levels (Samara-
Boustani et al., 2012). In addition. a link between BMI and HA seems to deserve 
attention, but the related mechanisms have not been clearly understood yet (Yasmin et 
al., 2013). 
We suggest that the relations with androgens are not independent and one single 
piece can interfere in several aspects so the exactly first step that can lead to female 
infertility is difficult to announce. 
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IMPACT OF HYPERANDROGENAEMIA ON WOMEN MORBIDITY, 
QUALITY OF LIFE AND ECONOMICS 
HA can negatively impact the quality of life of the affected women, being considered as 
a major cause of psychologic distress, with self-confidence, self-esteem and 
psychosexual implications that lead to changes in their lifestyle. It is also known that HA 
brings pronounced emotional repercussions, such as depression, frustration and anxiety, 
that lead to social eviction (Sonino et al., 1993; Girman et al., 1999; Thomas, 2004). 
Also, as we previously discussed, HA seems to be linked with other metabolic 
disturbances, such as IR and T2DM, dyslipidaemia and obesity, which constitute high 
prevalent issues in terms of morbidity and financial costs to the patient and to the national 
health system. In Portugal, 8495 mothers who gave birth have been studied. About 33% 
of them were overweight or obese before pregnancy (Alves et al., 2012). This is in 
agreement with the pandemics of obesity worldwide, with particular relief not only in 
decreased female fertility concomitantly with its association and probable cause of HA 
as we mentioned in this review, but also with consequences in embryo development 
(macrosomia, for instance) and in post-birth life, namely with higher prevalence of 
metabolic disturbances in the descendance.  
Therefore, HA constitutes a socioeconomic problem, as it affects this women’s 
behaviour and interaction with others and conducts to health consultations in several 
areas (Sonino et al., 1993).  
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CONCLUSIONS 
HA has an effective and important role in female fertility. However, it is hard to study this 
matter due to the lack of research reporting the specific underlying mechanisms. Those 
existing, indeed state that the excess in androgens can have a negative impact on 
miscarriage rate, ovarian reserve, follicle development, implantation success and 
pregnancy rates. Also, other metabolic disorders, such as obesity, hyperinsulinemia, 
T2DM, and dyslipidaemia seem to be in intimate relation with HA. 
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